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Abstract
Background Increased peripheral chemosensitivity
(PChS) has been proposed as mechanism underlying obe-
sity-related sympathoactivation, with insulin and/or leptin
as possible mediators. However, human data on PChS in
obesity are scarce. Therefore, we explored this issue in a
sample of 41 healthy men aged 30–59 years, divided
according to body fat percentage (fat %) into two
groups:\25 and C25 %.
Methods PChS was assessed using transient hypoxia
method [respiratory (PChS-MV), heart rate (PChS-HR),
and blood pressure (PChS-SBP) responses were calcu-
lated]. Baroreflex sensitivity (BRS-Seq) was assessed using
sequence method. Fasting plasma insulin and leptin levels
were measured. Homeostatic model assessment (HOMA)
was used to assess insulin sensitivity/resistance.
Results Individuals with C25 % body fat demonstrated
increased PChS-SBP (p\ 0.01), but unchanged PChS-MV
and PChS-HR (both p[ 0.4). PChS-SBP was related posi-
tively with anthropometric characteristics (e.g. waist cir-
cumference, fat %), plasma insulin and HOMA (all
p\ 0.05), and negatively with BRS-Seq (p = 0.001), but not
with plasma leptin (p = 0.27).
Conclusions In healthy men, overweight/obesity is
accompanied by augmented blood pressure response from
peripheral chemoreceptors, while respiratory and heart rate
responses remain unaltered. Hyperinsulinaemia and insulin
resistance (but not hyperleptinaemia) are associated with
augmented pressure response from chemoreceptors.
Keywords Peripheral chemoreflex  Leptin  Insulin 
Autonomic nervous system  Adipose tissue
Background
Hyperactivity of peripheral chemoreceptors has been
recently proposed as a pathophysiological mechanism
underlying sympathetically mediated diseases [1–3]. Obe-
sity is associated with chronically elevated sympathetic
activity which unfavorably affects the cardiovascular sys-
tem [4]. Thus, it would be tempting to hypothesize
deranged reflex responses from peripheral chemoreceptors
in obese subjects [5]. In fact, human data on the activity of
peripheral chemoreceptors in obesity are scarce, and usu-
ally related with respiratory, but not hemodynamic
responses from chemoreceptors [6–10].
In humans, peripheral chemoreceptors are mainly located
in the carotid bodies [11]. Considering carotid body-medi-
ated mechanisms of obesity-related sympathoactivation,
insulin and leptin seem to be of particular relevance since
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obesity is usually accompanied by hyperinsulinemia and
hyperleptinemia [12], and both, insulin and leptin have been
shown to exert sympathoexcitatory effects via direct action
on the carotid bodies in animal models [13–16]. Surpris-
ingly, to the authors’ knowledge there are no human data on
relations between peripheral chemoreflex sensitivity
(chemosensitivity) and insulin and leptin plasma levels.
Therefore, the study was aimed to explore the peripheral
chemoreflex sensitivity in healthy males across a broad
range of adipose tissue mass. More specifically, we
attempted: (1) to compare chemosensitivity between two
groups of subjects, with normal and increased body fat
content, and (2) to explore possible relations between
chemosensitivity and plasma levels of insulin and leptin in
the entire population studied. To provide more insight into
the effects of hyperinsulinemia and hyperleptinemia
against a background of autonomic nervous system activity
in obesity, heart rate variability and cardiac baroreflex
sensitivity were also evaluated.
Study population
Forty-one healthy males aged 30–59 years volunteered for the
study. The rather narrow age range was selected as we [17] and
others [18, 19] have reported that the peripheral chemoreflex
function in humans deteriorates with age. All subjects were
nonsmokers, normotensive, and none was taking any medi-
cations or reported any history of acute or chronic illness or
alcohol or drug addiction. The study was conducted at the
Department of Cardiology, 4th Military Hospital in Wroclaw
(Poland). The study protocol was approved by the local
Institutional Ethics Committee (Komisja Bioetyczna, Wro-
claw, Medical University). All subjects gave informed con-
sent in writing. The study was conducted in accordance with
the latest review of the Declaration of Helsinki.
Study protocol
All subjects were asked to refrain from caffeine and alco-
hol for at least 12 h before the study. Venous blood sam-
ples were collected in the morning (between 7:00 and 9:00)
after overnight fasting. Anthropometric characteristics:
height (cm), weight (kg), waist circumference (cm) and hip
circumference (cm) were measured using the standard
methods. Body mass index (BMI, kg/m2) and waist-to-hip
ratio (WHR) were calculated according to the standard
formulae (BMI = weight in kilograms/height in meters
squared, WHR = waist circumference in centimeters/hip
circumference in centimetres). Body fat percentage (%)
was estimated using a multi-frequency bioelectrical impe-
dance analyser (Quadscan 4000, Bodystat Ltd., Douglas,
UK). Measurement was carried out with subject lying
supine on a flat, nonconductive bed, for at least 15 min.
Study population was divided according to body fat per-
centage into two groups: with normal and with increased
body fat content (i.e. with body fat percentage\25
and C25 %, respectively). Unlike for BMI, there are no
commonly accepted cut-offs of body fat percentage for
classifying individuals as being overweight or obese. The
definition of obesity proposed by The American Society of
Endocrinologist is the body fat percentage of[25 % in men
[20]. Similar values have been reported in some large pop-
ulation-based studies (e.g. 25.9 %—the optimum threshold
for identifying men at increased cardiometabolic risk,
defined as the presence of metabolic syndrome and/or dia-
betes in the study by Lamb et al. [21]) we decided to set the
cut-off of body fat percentage at the level of 25 %.
After blood sampling and anthropometric measurement,
autonomic testing was performed in a quiet, light-attenu-
ated room with stable ambient temperature (*22 C).
Autonomic testing included: resting stage and transient
hypoxia stage, and was carried out with subject lying
supine and attached to the equipment described below (see
below, section: Study equipment).
Laboratory measurements
Fasting plasma glucose concentration (mmol/L) was mea-
sured using colorimetric assay with glucose oxidase
(Konelab Prime 60i/30i; Thermo Fisher Scientific, Wal-
tham, MA). Fasting plasma insulin level (lU/mL) was
measured using chemiliminescence on LIAISON Analyzer
(DiaSorin S.p.A., Saluggia, Italy). Fasting plasma leptin
level (ng/mL) was measured using ELISA (LDN Labor
Diagnostika Nord GmbH and Co. KG, Nordhorn, Ger-
many). The natural logarithms (ln) of serum insulin and
leptin were calculated and used in the analyses.
Insulin sensitivity/resistance was measured using the
homeostasis model assessment (HOMA-IR), according to
the formula: HOMA-IR = fasting plasma insulin (lU/mL)
9 fasting plasma glucose (mmol/L)/405 [22].
Study equipment
Non-invasive, continuous recording of hemodynamic
parameters: systolic blood pressure (SBP, mmHg), dias-
tolic blood pressure (DBP, mmHg), mean arterial pressure
(MAP, mmHg), stroke volume (SV, mL/beat), cardiac
output (CO, L/min) and systemic vascular resistance (SVR,
dyn 9 s/cm5) were obtained using Nexfin device (BMEYE
B.V., Amsterdam, Netherlands). ECG recording was per-
formed using ECG module for Nexfin device. Heart rate
(HR, bpm) was calculated from ECG recording.
Minute ventilation (MV, L/min) was calculated based on
instantaneous values of breathing rate and tidal volume,
measured continuously with a differential pressure
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transducer (FE141 Spirometer; ADInstruments, Sydney,
NSW, Australia) and a breathing circuit consisting of an
oronasal face mask (Hans Rudolph, Inc., Shawnee, KS,
USA) with two-way non-rebreathing T-shape valve (Hans
Rudolph) and a 1000 L/min flowhead (MLT3000L; ADIn-
struments) on the expiratory side of the valve. Continuous
measurement of end-tidal carbon dioxide concentration
(etCO2, mmHg) was provided by a capnograph (Capstar 100,
CWE Inc., Ardmore, PA, USA). Blood oxygen saturation
(SpO2, %) was measured continuously using an ear probe
connected to a pulse oximeter (Masimo Corporation Irvine,
CA, USA).
During the transient hypoxia stage, pure nitrogen was
administrated from 10-L gas cylinder via small-diameter
tube placed inside large-diameter breathing tube (ADIn-
struments) connected directly with a face mask. As shown by
in the previous studies from our laboratory [17, 23–25],
within this breathing circuit, administration of nitrogen with
a flow rate[15 L/s (regulated to the nearest 0.1 L) is suffi-
cient to cause a transient nitrogen accumulation in the circuit,
and in turn to evoke a substantial, short-lasting desaturation.
All data were recorded and stored at sampling frequency
of 1 kHz (16-bit resolution) using data acquisition system
(PowerLab 16/30, ADInstruments) and computer (Dell
Inc., Round Rock, TX, USA).
The first 3- to 5-min recording preceding the 15-min resting
stage was ignored and served only to familiarize the subject
with the experimental equipment. Resting values of HR, SBP,
DBP, MAP, SV, CO, SVR, MV, etCO2, and SpO2 were cal-
culated as arithmetic averages from 10-min recording of an
acceptable quality isolated from 15-min resting stage
recording. The same 10-min recording was used to calculate
heart rate variability cardiac baroreflex sensitivity.
Assessment of heart rate variability
Heart rate variability (HRV) parameters were used to
assess the sympathovagal interaction modulating cardio-
vascular function [26, 27].
The following HRV parameters were calculated: (1)
time domain parameters: average of all RR intervals (mean
RR, ms); standard deviation of all RR intervals (SDNN,
ms); number of pairs of adjacent NN intervals differing by
more than 50 ms (NN50 count); (2) frequency-domain
parameters: power of HRV spectrum within low frequency
range: 0.04–0.15 Hz (LF, ms2) and high frequency range:
0.15–0.4 Hz (HF, ms2) [26].
Frequency-domain parameters of HRV were calculated
using standard autoregressive methods [27]. SDNN reflects
overall autonomic modulation of the heart function,
whereas NN50 count and HF are considered as markers of
primarily vagal tone. The physiological mechanisms
underlying LF are less clear and include primarily
sympathetic or mixed, sympathetic and parasympathetic
influences [26].
Assessment of cardiac baroreflex sensitivity
Cardiac baroreflex sensitivity (BRS) was evaluated using
sequence method [28]. The sequence method is based on
the computer identification of spontaneously occurring
sequences of three or more consecutive heart beats, char-
acterized by either progressive rise in SBP (by at least
1 mmHg) with concomitant lengthening in RR interval (by
at least 5 ms) or progressive fall in SBP (by at least
1 mmHg) with concomitant shortening in RR interval (by
at least 5 ms). For each sequence selected, a slope of the
regression line relating RR interval to SBP is calculated,
and BRS is defined as the average of all slopes for all
sequences selected (BRS-Seq, ms/mmHg) [28, 29].
Assessment of peripheral chemoreflex sensitivity
The transient hypoxia method was used to evaluate a venti-
latory [30] and hemodynamic [23, 24] peripheral
chemosensitivity. During the transient hypoxia stage, sub-
ject was switched briefly from breathing with room-air to
breathing with pure nitrogen for 10–45 s. For each subject,
this procedure was repeated 5–7 times to achieve falls in
SpO2 with maximal desaturations varying from 65 to 85 %.
The length of subsequent periods of breathing with nitrogen
was adjusted ad hoc based on the fall in SpO2 observed
during the first, 10-s period. Subsequent periods of nitrogen-
breathing were separated by at least 5-min periods of room-
air breathing to allow for the measured parameters to return
to the baseline levels. Two components of hypoxia-induced
chemoreflex response were assessed: (1) ventilatory
response (increase in minute ventilation) and (2) hemody-
namic responses: HR response (increase in HR) and BP
response (increase in SBP) using the following calculations.
Ventilatory response For each nitrogen-breathing period,
three largest consecutive values of MV within 35-s after the
end of nitrogen-breathing period were averaged and plotted
against an associated nadir of SpO2 (providing Point A).
Similarly, baseline value of MV was plotted against baseline
value of SpO2 (providing Point B). Baseline values of MV
and SpO2 were defined as averages from 90-s period pre-
ceding the nitrogen-breathing period. Peripheral
chemosensitivity in terms of ventilatory response (PChS-
MV, L/min/SpO2 %) was defined as a slope of the regression
line relating all Points A to all Points B.
Hemodynamic responses Peripheral chemosensitivity in
terms of SBP response (PChS-SBP, mmHg/SpO2 %) and
HR response (PChS-HR, bpm/SpO2 %) were assessed
analogously as peripheral chemosensitivity in terms of
ventilatory response described above, with two differences:
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(1) 55-s period instead of 35-s period after nitrogen-breath-
ing period were used, and (2) the highest values of SBP (for
PChS-SBP) or HR (for PChS-HR) were used instead of the
averaged three largest consecutive values of MV.
Detailed description and validation of this method was
presented before [23, 24].
Statistical analysis
STATISTICA 10 (Statsoft, Tulsa, OK, USA) and
MATLAB (MathWorks, Natick, MA, USA) were used to
data and statistical analysis. The method of Kolmogorov–
Smirnov was used to determine whether the measured
parameters followed a normal distribution. Variables were
presented as mean ± standard deviation (for normally
distributed variables) or median with upper and lower
quartile (for non-normally distributed variables). Non-
normally distributed variables were logarithmically trans-
formed before statistical analysis (natural logarithm) and
proved to be normalized afterwards, before statistical
analysis. For all non-normally distributed variables, only
log-transformed values (ln) were used in the analyses.
Student’s t test was used for inter-group comparisons. For
the selected, statistically significant inter-group differ-
ences, the effect size was calculated using the method
proposed by Cohen [31], as standardized difference
between two means. Relations between variables were
tested in univariate models (r Pearson’s linear correlation
coefficients) and in multivariate models. p\ 0.05 was
considered statistically significant.
Results
Clinical characteristics in subjects with normal vs.
increased body fat content
Subjects with increased body fat content were character-
ized by higher body weight, waist circumference, body
mass index, and waist-to-hip ratio (all p\ 0.001). Respi-
ratory parameters at rest did not differ between groups (all
p[ 0.4). Heart rate, systolic, diastolic and mean arterial
pressure, and cardiac output were higher in subjects with
increased body fat content (all p\ 0.05). Higher values of
plasma insulin and leptin, and HOMA-IR were found in
those subjects (all p\ 0.05) (Table 1).
Peripheral chemoreflex sensitivity in subjects
with normal vs. increased body fat content
Subjects with increased body fat content displayed greater
BP response to hypoxia, as compared with the remaining
subjects (p = 0.004). The effect size for this difference
was large (Cohen’s d = 1.04), according to the criteria by
Cohen [31]. However, there were no inter-group differ-
ences in respiratory and HR responses to hypoxia (both
p[ 0.4) (Table 2).
Autonomic characteristics in subjects with normal
vs. increased body fat content
Parameters of overall HRV (mean RR, SDNN) were
reduced in subjects with increased body fat content (all
p B 0.05), suggesting depressed autonomic regulation of
heart function. In line with this notion, lower values of
vagally related parameters (NN50 count, BRS-Seq) were
found in those subjects. However, there were no differ-
ences in frequency-domain parameters of HRV (LF, HF,
both p[ 0.5) (Table 3).
Correlations between peripheral chemoreflex
sensitivity and selected variables
To investigate the possible determinants of augmented BP
response to hypoxia in subjects with increased body fat
content, correlatory analyses have been performed. In the
population studied, magnitude of BP response to hypoxia
was related positively with some anthropometric character-
istics (waist circumference, body fat percentage, waist to hip
ratio, all p\ 0.05), plasma insulin level and HOMA-IR
(both p\ 0.05), and negatively with some HRV parameters
(mean RR, SDNN, LF, all p\ 0.05), and cardiac baroreflex
sensitivity (p = 0.001). Of importance, plasma leptin level
was not related with PChS-SBP (p = 0.27) (Table 4, Fig. 1).
Multivariate regression model included all the variables
that appeared to significantly correlate with PChS-SBP in the
univariate models, with the exception of those which were
highly interrelated (arbitrary cut-off: r = 0.70). Two models
have been constructed. In the first model, including waist
circumference, BMI, and plasma insulin (ln), only plasma
insulin (ln) remained statistically significant (b = 0.39,
p = 0.04;R2 for the model = 0.25, p = 0.02). In the second
model, including waist circumference, BMI, and HOMA-IR,
only HOMA-IR remained statistically significant (b = 0.39,
p = 0.04; R2 for the model = 0.27, p = 0.03).
Discussion
The major findings of the study are that: (1) healthy men
with increased body fat content display augmented BP
response, but unchanged respiratory and HR responses
from peripheral chemoreceptors, and (2) elevated plasma
insulin level and reduced insulin sensitivity (but not plasma
leptin level) are associated with augmented BP response
from peripheral chemoreceptors in those subjects.
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Peripheral chemoreflex sensitivity in obesity
Our results suggest that being overweight/obese is
accompanied by a selective potentiation of BP response to
stimulation of peripheral chemoreceptors with hypoxia.
Literature data on the activity of hemodynamic com-
ponent of peripheral chemoreflex are scarce. Narkiewicz
et al. [10] have not found any significant difference
between normal-weight and obese subjects in BP and HR
responses to hypoxia. Such results stay in line with our
findings in regards to HR response, but not for BP
response. This discrepancy may be due to distinct
methodological approach. Narkiewicz et al. have used a
steady-state hypoxia method, with relatively weak hypoxic
Table 1 Clinical characteristics
in men with normal and
increased body fat content
Body fat percentage
\25 % (N = 27)
Body fat percentage
C25 % (N = 14)
p
Anthropometric parameters
Age (years) 46 ± 8 44 ± 8 0.38
Weight (kg) 81 ± 11 104 ± 16 \0.001
Waist (cm) 88 ± 9 109 ± 10 \0.001
BMI (kg/m2) 25.1 ± 2.7 33.7 ± 3.5 \0.001
Fat (%) 18.4 ± 3.4 30.1 ± 3.7 \0.001
WHR 0.90 ± 0.06 1.00 ± 0.05 \0.001
Respiratory parameters at rest
Breathing rate (breaths/min) 12 ± 4 12 ± 4 0.95
Minute ventilation (L/min) 11 ± 3 11 ± 4 0.68
etCO2 (mmHg) 36 ± 5 37 ± 3 0.78
SpO2 (%) 97 ± 1 96 ± 2 0.42
Haemodynamic parameters at rest
Heart rate (bpm) 65 ± 10 72 ± 7 0.02
Systolic blood pressure (mmHg) 117 ± 13 127 ± 13 0.02
Diastolic blood pressure (mmHg) 68 ± 7 74 ± 9 0.02
Mean arterial pressure (mmHg) 87 ± 10 95 ± 10 0.02
Stroke volume (mL/beat) 101 ± 10 103 ± 14 0.51
Cardiac output (L/min) 6.5 ± 0.8 7.4 ± 0.9 0.002
Systemic vascular resistance (dyn 9 s/cm5) 1090 ± 151 1047 ± 162 0.40
Blood parameters
Fasting plasma glucose (mmol/L) 101 ± 9 106 ± 17 0.31
Fasting plasma insulin (lU/mL) 7.9 (4.5, 10.7) 13.5 (10.6, 22.8) \0.001
Fasting plasma leptin (ng/mL) 4.9 (3.6, 7.0) 16.6 (7.3, 23.9) \0.001
HOMA-IR 2.24 ± 1.71 3.95 ± 2.06 0.04
Data are presented as a mean ± standard deviation or median with lower and upper quartile where
appropriate p values for inter-group comparisons using Student’s t test are presented
Waist waist circumference, BMI body mass index, Fat body fat percentage, WHR waist to hip ratio, etCO2
end-tidal CO2 concentration, SpO2 blood oxygen saturation, HOMA-IR homeostatic model assessment
Table 2 Peripheral
chemoreflex sensitivity in men
with normal and increased body
fat content
Body fat percentage
\25 % (N = 27)
Body fat percentage
C25 % (N = 14)
p
Peripheral chemoreflex sensitivity
PChS-MV (L/min/SpO2 %) 0.24 (0.15, 0.40) 0.26 (0.19, 0.33) 0.48
PChS-SBP (mmHg/SpO2 %) 0.53 ± 0.28 0.81 ± 0.27 0.004
PChS-HR (bpm/SpO2 %) 0.46 ± 0.19 0.50 ± 0.32 0.67
Data are presented as a mean ± standard deviation or median with lower and upper quartile where
appropriate; p values for inter-group comparisons using Student’s t test are presented
PChS-MV peripheral chemoreflex sensitivity in terms of respiratory response, PChS-HR peripheral
chemoreflex sensitivity in terms of heart rate response, PChS-SBP peripheral chemoreflex sensitivity in
terms of systolic blood pressure response
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stimulus (10 % O2 in N2) applied for three minutes.
Transient (acute) hypoxia method, which was used in our
study, includes several short (\1 min) episodes of breath-
ing with pure N2, and possibly results is much greater
activation of chemoreceptors [32].
Previous studies exploring the activity of respiratory
component of peripheral chemoreflex in obesity have
provided conflicting results, reporting either increased [7,
33], normal [6], or even decreased [34] ventilatory
responsiveness to hypoxia in obese subjects. However,
these (rather old) papers suffer from methodological
shortcomings (combining data from both sexes, effect of
aging or various co-morbidities, e.g. hypertension,
obstructive apnea/hypopnea syndrome) [8]. Two well-
controlled studies by Narkiewicz et al. [10] and Buyse et al.
[8] have found no significant effect of obesity on hypoxic
ventilatory response. Such results stay in line with our
study, but, as mentioned above, direct comparison of the
results may be misleading due to different methodology
applied to assess chemosensitivity.
Important strengths of our study need to be emphasized.
First, we defined normal and increased body fat based on
bioelectrical impedance analysis, instead of body mass
index. Second, we assessed both, ventilatory and hemo-
dynamic components of peripheral chemoreflex. Previous
studies from our laboratory [17, 24] and experimental data
from animal models [35–37] suggest that respiratory, BP
and HR responses from peripheral chemoreceptors are
conveyed by at least partially distinct pathways, and some
pathophysiological processes may disturb one component
of the peripheral chemoreflex, leaving the other intact.
The magnitude of potentiation of the pressure response
found in our study in obese healthy subjects (mean:
0.81 ± 0.27 mmHg/SpO2 %) is in the range of reported for
patients with chronic systolic heart failure (CHF)
(Niewinski et al. [23]: mean: 0.67 mmHg/SpO2 %) or
arterial hypertension (Tubek et al., unpublished: mean:
1.06 mmHg/SpO2). A growing body of evidence suggests
that the hypersensitivity of the carotid bodies contributes to
increased sympathetic tone in certain cardiovascular dis-
eases, and surgical removal of the carotid body may be
considered as a novel therapeutic approach aimed to restore
autonomic balance in those patients [3]. Our finding of the
enhanced pressure response to hypoxia in obese subjects
indicates that similar mechanism may be involved in the
development of obesity-related sympathoactivation, as
proposed by Porzionato [5]. Interestingly, however, we did
not observe a parallel increase in ventilatory chemosensi-
tivity in obese subjects. The reason of such discrepancy
remains elusive and further studies are needed.
Relations between insulin/leptin and peripheral
chemoreflex sensitivity in obesity
Both, insulin and leptin have been proposed as key medi-
ators triggering sympathetic overactivity in obese subjects
via direct action on the peripheral chemoreceptors in the
carotid bodies [5, 15]. However, possible relations between
both, plasma insulin and leptin levels and peripheral
chemoreceptors sensitivity have not been investigated in
humans. We have shown, for the first time, in a large
sample of healthy males across a broad range of adipose
tissue mass that plasma insulin level, but not leptin level is
related positively with BP responsiveness of peripheral
chemoreceptors.
The sympathoexcitatory effects of insulin are well
established [38]. Acute hyperinsulinemia has been shown
to increase plasma catecholamine concentration [39],
plasma norepinephrine spillover [40], and muscle sympa-
thetic nerve activity (MSNA), measured directly using
microneurography technique [41, 42] in humans. Recent
study by Ribeiro et al. [15] on rats has raised the possibility
Table 3 Autonomic
characteristics in men with
normal and increased body fat
content
Body fat percentage
\25 % (N = 27)
Body fat percentage
C25 % (N = 14)
p
Heart rate variability at rest
Mean RR (ms) 950 ± 133 831 ± 95 0.007
SDNN (ms) 39 ± 9 33 ± 8 0.04
NN50 count 28 (7, 57) 17 (1, 27) 0.03
LF (ms2) 700 (259, 1260) 775 (354, 1203) 0.82
HF (ms2) 288 (185, 713) 156 (83, 520) 0.51
Baroreflex sensitivity at rest
BRS-Seq (ms/mmHg) 12.9 ± 6.1 7.7 ± 2.7 0.006
Data are presented as a mean ± standard deviation or median with lower and upper quartile where
appropriate; pvalues for inter-group comparisons using Student’s t test are presented
Mean RR mean duration of RR interval, NN50 count number of pairs of adjacent RR intervals differing by
more than 50 ms, LF low frequency range of heart rate variability spectrum, HF high frequency range of
heart rate variability spectrum, BRS-Seq cardiac baroreflex sensitivity assessed by the sequence method
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that carotid bodies play an important role in mediating the
sympathoexctitatory effects of insulin. The authors were
first to identify insulin receptors in the rat carotid bodies,
and to demonstrate, that insulin administration increases
activity of the carotid bodies, initiating a release of neu-
rotransmitter and leading to hyperventilation. Even more
importantly, in this study bilateral carotid body resection
has prevented the development of hypertension and insulin
resistance in rats on hypercaloric diet, thereby emphasizing
a physiological significance of this mechanism.
A growing body of evidence supports the sympathoex-
citatory effects of leptin [43]. In animals, intravenous [44–
46] or central [42–49] leptin infusion caused marked
sympathoactivation, and this was accompanied by hemo-
dynamic consequences (increase in BP and HR) in some
[45], but not all studies [46]. In humans, hyperleptinaemia
has been reported to correlate positively with sympathetic
activity, as assessed by heart rate variability [46, 50],
plasma norepinephrine spillover [52], and direct
microneurographic recordings [53], and genetically based
human leptin deficiency is accompanied by substantially
attenuated sympathetic tone [54]. Recently, Machleidt
et al. [55] have shown that, in lean healthy men, acute
intravenous infusion of leptin directly increases MSNA.
Direct role for the carotid bodies in mediating sympa-
thoexcitatory effects of hyperleptinaemia has been pro-
posed [5], as leptin receptors have been identified in rat and
human glomus cells [16], and intravenous infusion of
leptin have been reported to activate these cells [13, 14].
Microinjection of leptin into the nucleus tractus solitarii
has potentiated BP response to stimulation of peripheral
chemoreceptors in rats [56].
Of relevance, virtually all studies investigating the
autonomic effects of leptin have ignored a possible impact





































































































































































































































































































































































































































































































































































































































































































Fig. 1 Relation between plasma insulin level (natural logarithm) and
blood pressure response to hypoxia in the population studied
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Also, depressed cardiac baroreflex sensitivity found in
men with increased body fat content may be considered as a
mechanism underlying potentiated response to hypoxia in
these subjects. This possibility cannot be excluded, espe-
cially in the light of robust negative relation between PChS-
SBP and BRS-Seq found in this study. However, experi-
mental data suggests that, during and after hypoxia,
baroreflex is resetted toward higher levels of BP [58, 59],
and thereby does not abolish the hypoxia-induced rise in BP.
Autonomic control of the heart in obesity
Reduced vagal outflow to the heart, and blunted cardiac
baroreflex sensitivity are well-established hallmarks of
human and experimental animals obesity [60–62], and have
been confirmed in the present study. Of note, lack of
concomitant reduction in LF—a marker of sympathetic
control of the heart—is in agreement with other reports
suggesting that sympathetic outflow is controlled in a tissue
specific manner, and cardiac sympathetic modulation is
unchanged or even reduced in obesity, despite generalized
sympathetic activation [4, 63].
Study limitations
We acknowledge that our study is not without limitations.
First, in this study design no cause-effect relationship
would be drawn. Second, for uniformity, only male sub-
jects were enrolled in the study. Therefore, we acknowl-
edge that our results cannot necessarily be extrapolated to
women. Third, the concentration of the soluble leptin
receptor was not measured. Such information would
increase insight into the ability of leptin to penetrate
blood–brain barrier, and to act on the central nervous
system structures [64]. Fourthly, a direct measurement of
MSNA using microneurography technique [65] would
provide a better estimation of sympathovagal balance than
indirect methods as heart rate variability [66]. Given the
observed clustering of obesity, hypertension, inflammation,
intermittent hypoxia, hyperglycemia, and insulin and leptin
resistance, studies in humans in this area are extremely
difficult and require innovative experimental approaches.
The fact that the magnitude of the pressure response to
hypoxia was correlated with body fat mass, but not with
plasma leptin appears counterintuitive, as leptin is produced
in direct proportion to the amount of adipose tissue, and
robust, linear relation between body fat mass and plasma
leptin is usually observed [12]. Such relation was also found
in our study [fat % vs. plasma leptin (ln), r = 0.67,
p\ 0.001]. From the physiological perspective, at least two
explanations may be considered: (1) other fat-related factors
(according to the results of the multiple regression—mainly,
plasma insulin or insulin sensitivity) seem to contribute
more to the pressure response to hypoxia than plasma leptin
level, (2) altered sensitivity of leptin receptors in the carotid
body may distort a possible relation between pressure
response to hypoxia and plasma leptin level.
The study adds another important piece to the complex
influence of insulin and leptin on autonomic reflex control
of cardiorespiratory function. Both, insulin and leptin have
been considered the key players linking obesity, autonomic
derangement, and sympathetically mediated diseases (e.g.
hypertension). Nevertheless, the exact mechanisms of its
action on autonomic nervous system function remain elu-
sive and further detailed studies in this area are required.
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